Bionano Genomics appoints Al Luderer as interim CEO, ensuring smooth leadership transition.

Bionano Genomics announced that Al Luderer, Ph.D., chairman of its Board, has been appointed interim president and CEO effective May 5, 2026, succeeding Erik Holmlin, Ph.D., who remains as an advisor. Luderer, with over 30 years in biotech and deep company knowledge, will lead the company through this transition while the board searches for a permanent CEO. The company expects no disruption to its business operations during this leadership change. This move aims to maintain momentum in Bionano's mission to advance genome analysis technologies and growth.